Iterum Therapeutics Introduces ORLYNVAH™, the First Oral Penem Antibiotic for uUTIs in the U.S.

Iterum Therapeutics has launched ORLYNVAH, the first oral penem antibiotic in the US, for adult women with uncomplicated urinary tract infections (uUTIs) caused by Escherichia coli, Klebsiella pneumoniae or Proteus mirabilis. The FDA approved the drug in October 2024, and it offers a new option for patients and physicians facing a shrinking arsenal of effective oral therapies. The launch addresses the urgent need for innovation in this space, with 60% of women experiencing a uUTI in their lifetime and 44% experiencing three or more episodes annually.